139968-49-3
139968-49-3
Chemical Structure
Metaflumizone
Synonym(s): BAS-320I
- CAS No.: 139968-49-3
- Formula:C24H16F6N4O2
- Molecular Weight:506.40
IUPAC Name: (Z)-2-(2-(4-cyanophenyl)-1-(3-(trifluoromethyl)phenyl)ethylidene)-N-(4-(trifluoromethoxy)phenyl)hydrazine-1-carboxamide
InChIKey: MIFOMMKAVSCNKQ-HWIUFGAZSA-N
SMILES: FC(F)(F)C1=CC(/C(CC2=CC=C(C=C2)C#N)=N\NC(NC3=CC=C(C=C3)OC(F)(F)F)=O)=CC=C1
Biological Activity: Metaflumizone is a semicarbazone insecticide, acts as a potent sodium channel blocker[1].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Metaflumizone | 95.14% | Metaflumizone is a semicarbazone insecticide, acts as a potent sodium channel blocker. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Metaflumizone (Standard) | ≥98% | Metaflumizone (Standard) is the analytical standard of Metaflumizone. This product is intended for research and analytical applications. Metaflumizone is a semicarbazone insecticide, acts as a potent sodium channel blocker. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Metaflumizone-d4 | Metaflumizone-d4 is deuterium labeled Metaflumizone. Metaflumizone is a semicarbazone insecticide, acts as a potent sodium channel blocker. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
DJ-V-159 | 99.94% | DJ-V-159 is an agonist for G protein-coupled receptor family C group 6 member A (GPRC6A). | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
UC-1728 | 99.88% | UC-1728 is a potent rabbit soluble epoxide hydrolase (sEH) inhibitor, with an IC50 of 2 nM on rabbit liver. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
MEIS-IN-1 | 99.32% | MEIS-IN-1 is a potent myeloid ecotropic viral integration site (MEIS) inhibitor to induce murine and human hematopoietic stem-cell expansion. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
SC-43 | 99.01% | SC-43, a Sorafenib derivative, is a potent and orally active SHP-1 (PTPN6) agonist. SC-43 inhibits the phosphorylation of STAT3 and induces cell apoptosis. SC-43 has anti-fibrotic and anticancer effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
STAT3-IN-48 | 98.64% | STAT3-IN-48 is a Sorafenib analogue and potently inhibits the phosphorylation of STAT3. STAT3-IN-48 induces cell apoptosis through SHP-1 dependent STAT3 inactivation. STAT3-IN-48 does not inhibit kinase activity and has anticancer effects. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
VS 8 | VS 8 (Compound VS 8) is a potent, orally active VEGFR-2 inhibitor with significant anti-angiogenic effects. VS 8 induces cancer cell apoptosis and migration. VS 8 is active against CSCs (Cancer stem cells). | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
EIF2α activator 2 | 99.57% | EIF2α activator 2 (Compound 1) is an activator of eukaryotic initiation factor 2 alpha (eIF2α) phosphorylation. EIF2α activator 2 exhibits high potency in SRB cell proliferation assays (IC50=0.46 μM). EIF2α activator 2 exhibits antiproliferative activity againist K562 and PBMC cells with IC50s of 4.79 and 10.52 μM, respectively. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
CDK8-IN-11 | 98.18% | CDK8-IN-11 is a potent and selective CDK8 inhibitor with an IC50 value of 46 nM. CDK8-IN-11 inhibits WNT/β-catenin signaling pathway. CDK8-IN-11 can be used in the research of colon cancer. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
sEH-IN-1 | sEH-IN-1 (example 67) is a soluble epoxide hydrolase (sEH) inhibitor. sEH-IN-1 can be used in the research of sEH-mediated diseases such as hypertension, cardiovascular disease, inflammation, diabetes, and so on. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
AFG210 | AFG210 is a potent multi-target kinase inhibitor that primarily inhibits Abl kinase (IC50=330 nM), and also has inhibitory effects on other kinases such as B-Raf, C-Raf, FGFR-1, RET and VEGF receptors. AFG210 can be used to study chronic myeloid leukemia and other diseases with abnormal activation of Abl kinase. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
